TruAlt Bioenergy
TruAlt Bioenergy Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
The short version
TruAlt Bioenergy expects to increase ethanol capacity utilization from current ~60% to 80-90% in upcoming quarters, with Q2 FY27 sales projected at around 11 crore litres (Page 22). The company expects to increase ethanol production and improve capacity utilization from the current 60% to around 80-90%, which should boost revenues and profits in upcoming quarters.
From TruAlt Bioenergy's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- TruAlt Bioenergy expects to increase ethanol capacity utilization from current ~60% to 80-90% in upcoming quarters, with Q2 FY27 sales projected at around 11 crore litres (Page 22).
- The company has 44 crore litres of ethanol orders on hand for FY27, expecting volumes higher than last year's 40 crore litres (Page 8).
- No further capex planned in ethanol segment; focus on utilizing existing capacity fully (Page 7).
- CBG revenues to begin from Q4 FY27 with ongoing capex of ~INR700 crores, expanding compressed biogas business (Page 7).
- SAF (Sustainable Aviation Fuel) business involves a planned INR2,000 crore capex with revenues anticipated starting FY29, expected asset turnover of 1x (Page 7).
- Potential growth if ethanol blending percentage increases beyond 20% (Page 24).
- No new ethanol capacity additions expected across the industry, except a few plants yet to commission adding 8-10 crore litres per annum (Page 24).
Profitability & Margins
See what TruAlt Bioenergy said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No further capex planned in the ethanol segment as all capacities are commissioned and ready for utilization.
- INR ~700 crores capex underway in the CBG segment through two JVs:
- - INR 330 crores for four 20 TPD CBG plants with Sumitomo.
- - INR 425 crores for six 10 TPD CBG plants with GAIL.
- CBG capex funded at 70:30 debt-to-equity; TruAlt holds 51% stake.
- INR ~2,000 crores capex planned for Sustainable Aviation Fuel (SAF) production, with EPC contract awards awaited.
- SAF capex expected to start within 2-3 months, with revenues anticipated by FY29 (end 2028).
- No new capacity additions expected in ethanol; growth expected from increased utilization and existing plants.
- Technology tie-up with Indian Institute of Science for biomass oxy-steam gasification for green hydrogen, but no progress due to lack of market/supply chain.
Top-ranked in Agricultural Food & other Products
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what TruAlt Bioenergy said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- TruAlt Bioenergy currently has an order book of approximately 44 crore litres of ethanol for FY2027.
- This includes orders from Oil Marketing Companies (OMCs), private sector, and ENA sales.
- In Q1 FY27, they sold about 8.29 crore litres and expect around 11 crore litres of sales in Q2 FY27, indicating a strong pipeline.
- There is an ongoing 15 crore litre spillover order from the previous period, currently under discussions with OMCs, expected to be realized soon.
- The company aims to increase capacity utilization from current ~60% toward 90-95% to fulfill higher orders.
- No significant new capacity additions are planned in ethanol; growth will come from better capacity utilization and existing pending orders.
TruAlt Bioenergy — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹596 Cr, net profit ₹61 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What TruAlt Bioenergy Ltd's management said in earlier quarters
Others in Agricultural Food & other Products this season
- Chamanlal Setia Exports Ltd (Q1 FY27)
Management is optimistic about sustaining EBITDA margins (12-14%) with profitable business mix. Key concall takeaways from Chamanlal Setia's Q1 FY27 earnings…
- Kaveri Seed Company Ltd (Q1 FY27)
100 crores revenue in vegetables within 3 to 5 years. Key concall takeaways from Kaveri Seed Company Ltd's Q1 FY27 earnings call — and how it ranks against…
- Regaal Resources Ltd (Q1 FY27)
Value-added product share rising sharply from 3% in FY’26 to 20-22% in FY’27, driving better margins. Key concall takeaways from Regaal Resources Ltd's Q1 FY27…
- Triveni Engineering and Industries Ltd (Q1 FY27)
The closing order book for Triveni Engineering's water business stood at a healthy ₹1,472 crores as of Q1 FY27. Key concall takeaways from Triven.Engg.Ind.'s…
Frequently Asked Questions
What were TruAlt Bioenergy Q1 FY27 results?
TruAlt Bioenergy expects to increase ethanol capacity utilization from current ~60% to 80-90% in upcoming quarters, with Q2 FY27 sales projected at around 11 crore litres (Page 22). The company expects to increase ethanol production and improve capacity utilization from the current 60% to around 80-90%, which should boost revenues and profits in upcoming quarters.
What is TruAlt Bioenergy share price analysis?
TruAlt Bioenergy currently shows a neutral. The stock trades at a P/E of 24.5 with a market cap of ₹3,826 Cr. Investors should review the full earnings analysis for detailed insights.
Is TruAlt Bioenergy planning capital expenditure?
No further capex planned in the ethanol segment as all capacities are commissioned and ready for utilization.
Keep TruAlt Bioenergy on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.